



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/217948/2024
EMA/H/C/004936

Rozlytrek (*entrectinib*)

An overview of Rozlytrek and why it is authorised in the EU

What is Rozlytrek and what is it used for?

Rozlytrek is a cancer medicine. It can be used for treating patients from 1 month of age with solid tumours (cancer growths) that have a genetic abnormality called *NTRK* gene fusion. Rozlytrek is for use in patients with tumours that have spread nearby or to other parts of the body (metastatic cancer) or when removing the tumour by surgery could cause severe harm. It should be used only if the patient has not been treated previously with a medicine that works in the same way as Rozlytrek and other treatments are not suitable.

Rozlytrek can also be used for treating adults with advanced non-small-cell lung cancer that has a genetic abnormality called *ROS1* gene fusion. It should be used only if the patient has not been treated previously with a medicine that blocks *ROS1*.

Rozlytrek contains the active substance entrectinib.

How is Rozlytrek used?

Rozlytrek can only be obtained with a prescription and treatment should be started by a doctor who is experienced in the use of cancer medicines.

Rozlytrek is available as capsules and granules taken once daily. Treatment should continue until the medicine stops working. The doctor may reduce the dose, interrupt treatment or stop it altogether if the patient has certain side effects.

For more information about using Rozlytrek, see the package leaflet or contact your doctor or pharmacist.

How does Rozlytrek work?

Cancers with *NTRK* gene fusion or *ROS1* gene fusion produce abnormal proteins that cause an uncontrolled increase of cancer cells. Entrectinib, the active substance in Rozlytrek, blocks the action of these proteins and so prevents the increase in cancer cells. This slows down cancer growth.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



What benefits of Rozlytrek have been shown in studies?

Solid tumours with *NTRK* gene fusion

Ongoing studies involved a total of 74 adults with advanced solid tumours with *NTRK* gene fusion in whom previous treatment had stopped working or other treatment was not suitable. Patients received Rozlytrek until it stopped working or caused unacceptable side effects. Out of a total of 74 patients, the cancer shrank in 64% of patients and the average duration of response (period during which the cancer did not grow) was 12.9 months. Rozlytrek was not compared with another treatment for solid tumours.

Supporting studies indicate that the medicine is expected to work in the same way in patients from 12 years of age.

The effectiveness of Rozlytrek was investigated in two studies that involved a total of 44 children, 38 of whom were younger than 12 years of age. All patients had a solid tumour with *NTRK* gene fusion with no satisfactory treatment option available. Patients were followed for an average of 24 months. The analysis showed that about 73% of patients had a response to treatment (when the cancer shrinks or disappears), with 45% having a complete response, meaning that there was no sign of the cancer at the time of the analysis. Rozlytrek was not compared with another medicine.

Non-small-cell lung cancer with *ROS1* gene fusion

Studies involved a total of 94 patients with advanced or metastatic non-small-cell lung cancer with *ROS1* gene fusion. Patients were followed up for more than 12 months and they received Rozlytrek until it stopped working or caused unacceptable side effects. The cancer shrank in 73% of patients and the average duration of response was 16.5 months. The studies did not compare Rozlytrek with another treatment for non-small-cell lung cancer.

What are the risks associated with Rozlytrek?

The most common side effects with Rozlytrek (which may affect more than 1 in 5 people) are tiredness, constipation, dysgeusia (taste disturbances), oedema (swelling with fluid retention), dizziness, diarrhoea, nausea (feeling sick), dysaesthesia (unpleasant and abnormal feeling when touched), dyspnoea (difficulty breathing), anaemia (low red blood cell count), increased weight, increased levels of creatinine in the blood (a possible sign of kidney problems), increased levels of liver enzymes (a possible sign of liver problems), pain, joint pain, cognitive disorders (problems with ability to think, learn and remember), vomiting, cough, and fever.

The most common serious side effects with Rozlytrek (which may affect more than 1 in 50 people) are lung infection, dyspnoea, cognitive impairment, fractures, fever and pleural effusion (build-up of fluid around the lungs).

For the full list of restrictions and side effects of Rozlytrek, see the package leaflet.

Why is Rozlytrek authorised in the EU?

The European Medicines Agency considered that in patients with solid tumours with *NTRK* gene fusion, treatment with Rozlytrek is of benefit when other treatment is not available or does not work. Although data in children are limited, the effect seen in children is consistent with that seen in adolescents and adults. More information is needed on the medicine's effect on tumours in different sites and when other gene abnormalities are present. For non-small-cell lung cancer with *ROS1* gene fusion, results currently available suggest that treatment with Rozlytrek can reduce the size of tumours. At the time

of approval, there were very limited treatment options for patients with these types of cancer. The side effects of Rozlytrek are considered manageable.

Therefore, the Agency decided that Rozlytrek's benefits are greater than its risks and it can be authorised for use in the EU. Rozlytrek has been given 'conditional authorisation'. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while waiting for further evidence.

The company must provide further data on Rozlytrek. It must submit the results from ongoing studies on the effectiveness and safety of Rozlytrek in adults and children who have solid tumours with *NTRK* gene fusion. Every year, the Agency will review any new information that becomes available.

What measures are being taken to ensure the safe and effective use of Rozlytrek?

In addition to the data requested as part of the conditional marketing authorisation, the company that markets Rozlytrek will provide results from a study comparing the effectiveness of Rozlytrek with crizotinib (another cancer medicine) in patients with non-small-cell lung cancer with *ROS1* fusion whose disease has spread to the brain.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rozlytrek have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rozlytrek are continuously monitored. Side effects reported with Rozlytrek are carefully evaluated and any necessary action taken to protect patients.

Other information about Rozlytrek

Rozlytrek received a conditional marketing authorisation valid throughout the EU on 31 July 2020.

Further information on Rozlytrek can be found on the Agency's website:

ema.europa.eu/medicines/human/EPAR/rozlytrek.

This overview was last updated in 06-2024.